Symposia

Schedule, times and titles are subject to modification!

S1 - Diseases of the Oral Mucosa
Thursday, 17 May 2007
8.30 – 10.00  Hall H

Chair:  A. Brasie (Ankara, Turkey)
Co-Chairs:  D. Parent, (Brussels, Belgium), S. Challacombe (London, UK)

Learning objectives:
After this session the attendee will:

1. be able to diagnose and manage common and unusual viral oral diseases,
2. be able to counsel patients about the risk of oral HIV transmission and oral or genital HSV transmission,
3. be acquainted with a new method to study the effect of anti-viral drugs under conditions close to the in vivo cellular environment.

Description:
After a clinicopathological overview of common and unusual oral viral diseases, the symposium will address various aspects of viral infections: oral and oral/genital transmission (HIV, HSV), oral clinical manifestations (HPV 13-32 and HCV infections), and their management (focal epithelial hyperplasia and HSV infections in immunocompromised patients). Can HIV induce an infection in the oral cavity? Does HSV asymptomatic shedding play a role in HSV transmission? Why is the prevalence of HSV1 in genital infection on the increase? Are factors such as local trauma, genetic predisposition and immune status responsible for Heck’s disease? Could manifestations such as oral lichen planus, oral lichenoid lesions and salivary glands disease be considered part of the wide range of extrahepatic manifestations in HCV infections? Finally, the attendees will be introduced to a new technique that provides a better understanding of the pathophysiology of viral diseases. It consists of three-dimensional cell cultures now used in virology for the development of new anti-viral drugs.

8.30	S1.1	Viral diseases of the oral mucosa: a clinicopathological overview. R. Anadolu-Brasie (Ankara, Turkey)
8.42	S1.2	Oral HIV transmission: an update. J Campo (Madrid, Spain)
8.52	S1.3	HSV oral and oral/genital transmission: the role of HSV asymptomatic shedding. D. Parent (Brussels, Belgium)
9.02	S1.4	Focal epithelial hyperplasia: presentation, diagnosis and management. T. Lombardi (Geneva, Switzerland)
9.13	S1.5	Anti-HSV treatment in immunocompromised patients. S. Challacombe (London, UK)
9.25	S1.6	Oro-facial manifestations of HCV infections. M. Mignogna (Naples, Italy)
9.37	S1.7	Unusual viral oral diseases. Roy S. Rogers III (Rochester, USA)
9.49	S1.8	Three-dimensional culture models for human viral diseases and anti-viral drug development. R. Snoeck (Leuven, Belgium)

S2 - Adverse Drug Reactions: How to Avoid, How to Diagnose, and How to Treat
Thursday, 17 May 2007
10.15 – 11.45  Hall G

Chair:  H. Hintner (Salzburg, Austria)
Co-Chairs:  A. Bircher (Basel, Switzerland), S.M. Breathnach (London, UK)

Learning Objectives:
At this session the attendee will learn about:

1. the avoidance of adverse drug reactions (ADR) – by pharmacogenetics (how to avoid),
2. the value of histopathology in the diagnosis of ADR’s (how to diagnose),
3. treatment news for ADR’s (how to treat).

Description:
This very short symposium will be focused on new or rare aspects of adverse drug reactions. The impact of pharmacogenetics on drug allergy and the contribution of histopathology to their diagnosis will be discussed. Of great interest is the potential existence of an allergy to the iodine contained in drugs. Finally, new aspects of diagnostic procedures in general, and of therapeutic approaches, will be discussed.

10.15	S2.1	Impacts of pharmacogenetics on drug allergy. H. Merk (Aachen, Germany)
10.30	S2.2	The contribution of histopathology. M. Emberger (Salzburg, Austria)
10.45	S2.3	Allergy to iodine in drugs: Fact or fiction. A. Bircher (Basel, Switzerland)
11.00	S2.4	New aspects of diagnostic procedures. A. Barbaud (Nancy, France)
11.30	S2.5	Therapeutic approaches: is there anything new? P. Friedmann (Southampton, UK)
11.45		Discussion

S3 - Treatment of Skin Disorders in Pregnancy
Thursday, 17 May 2007
8:30 – 10.00  Hall G

Chair:  M. Black (London, UK)
Co-Chair(s):  C. Ambros-Rudolph (Graz, Austria), G. Kirtschig (Amsterdam, Netherlands)

Learning objectives:
After this session the attendee will be able to:

1. diagnose and treat the specific dermatoses of pregnancy,
2. appropriately treat a pregnant patient with pruritus,
3. select the suitable therapy for frequently encountered skin problems in pregnancy, including skin infections and changing moles/melanoma.

Description:
This session will outline the investigation and management of a pregnant woman presenting with a pruritic skin eruption. Particular attention will be given to the specific dermatoses of pregnancy, which have been recently reclassified, and include pemphigoid gestationis, polymorphic eruption of pregnancy, atopic eruption of pregnancy, and intrahepatic cholestasis of pregnancy. The attendees will learn to differentiate and accurately manage various pruritic skin disorders. At the end of the session they will be able to choose the correct therapeutic regimen for each condition and inform the mother competently about the potential risks for the fetus or risks after pregnancy. Furthermore, the symposium will address the treatment of other common skin problems in pregnancy, including skin infections and changing moles/melanoma, and will offer useful information about dermatological treatment during pregnancy.

8.30	S3.1	Introduction and classification of skin disorders in pregnancy. M. M. Black, (London, UK)
8.40	S3.2	The specific dermatoses of pregnancy I - Pemphigoid gestationis and polymorphic eruption of pregnancy. S. A. Vaughan-Jones (Chertsey, UK)
8.50	S3.3	The specific dermatoses of pregnancy II - Atopic eruption of pregnancy and intrahepatic cholestasis of pregnancy. C. M. Ambros-Rudolph (Graz, Austria)
9.00	S3.4	Cutaneous infections in pregnancy. R.R. Müllegger (Wiener Neustadt, Austria)
9.10	S3.5	Changing moles and melanoma in pregnancy. G. Argenziano (Naples, Italy)
9.20	S3.6	Clues to dermatological treatment in pregnancy, G. Kirtschig (Amsterdam, Netherlands)
9.30		Interactive discussion

S4 - Scleroderma
Thursday, 17 May 2007
15.00 – 16.30  Hall L

Chair:  N. Hunzelmann (Cologne, Germany)
Co-Chairs: S. Majewski (Warsaw, Poland), S. Ullman (Copenhagen, Denmark)

Learning objectives:
After this session the attendee will be able to:

1. identify subsets of systemic scleroderma,
2. treat organ manifestations in systemic scleroderma,
3. treat local scleroderma in children.

Description:
Scleroderma is a descriptive term summarizing a spectrum of diseases. This session will focus on systemic and local scleroderma, with special emphasis on new classifications and the development of therapeutic options. Although many aspects of the complex pathophysiological events are still unclear, better understanding of the diseases and large international studies have disclosed successful symptomatic treatment modalities. However, prerequisites for the initiation of such therapies are early diagnosis and, in the case of systemic scleroderma, follow-up studies focusing on systemic involvement of internal organs in systemic scleroderma. Well defined European-wide clinical trials have also disclosed sub-classification of local scleroderma in children, and permit identification of those patients who require early systemic therapy.

This session will highlight the role of experienced dermatologists in the management of patients with scleroderma, and focus on recent advances in early diagnosis and symptomatic treatment of this chronic fibrosing disease.

15.00		Introduction. N. Hunzelmann (Cologne, Germany)
15.05	S4.1	Systemic scleroderma: Classification and new subsets. C. Frances (Paris, France)
15.25	S4.2	Systemic scleroderma: Essentials of therapy. N. Hunzelmann (Cologne, Germany)
15.45	S4.3	Classification of localized scleroderma. S. Ullman (Copenhagen, Denmark)
15.55	S4.4	Localized scleroderma in children. F. Zulian (Padova, Italy)
16.10		Summary. S. Majewski (Warsaw, Poland)

S5 - Diagnosis and Management of Autoimmune Bullous Diseases in Clinical Practice
Thursday, 17 May 2007
8.30 – 10.00  Hall M

Chair:  L. Borradori (Geneva, Switzerland)
Co-Chairs: P. Joly (Rouen, France), S. Karpati (Budapest, Hungary)
 
Learning objectives:
After this session the attendee will:

1. be aware of advances in the field of autoimmune blistering diseases,
2. know the clinical and misleading presentations of autoimmune blistering diseases,
3. know which exams are required to diagnose these conditions and how to manage them.

Description:
The aim of the session is to provide knowledge for the practicing dermatologist. Common as well as misleading presentations of autoimmune blistering diseases will be reviewed, and the differential diagnosis discussed.
Emphasis will be given to the diagnosis of these diseases, the exams required, and how to manage patients affected by these disorders; guidelines for the use of systemic drugs will be discussed.

8.30	S5.1	Advances in Pemphigus and pemphigoid. L. Borradori (Geneva, Switzerland)
8.48	S5.2	Vesiculo-bullous eruptions in clinical practice: Rare diagnoses not to be missed. H. Hintner (Salzburg, Austria)
9.06	S5.3	Dermatitis herpetiformis, a diagnostic challenge. S. Karpati (Budapest, Hungary)
9.24	S5.4	How to diagnose autoimmune blistering diseases in practice. M. Jonkman (Groeningen, Netherlands)
9.42	S5.5	Guidelines for the use of systemic drugs in practice. P. Joly (Rouen, France)

S6 - Management of Cutaneous Lymphoma
Thursday, 17 May 2007
10.15 – 11.45  Hall O

Chair:  R. Willemze (Leiden, Netherlands)
Co-Chairs:  M. Bagot (Créteil, France), R. Dummer (Zurich, Switzerland)

Learning objectives:
After this session the attendee will be able to:

1. recognize the most common types of primary cutaneous lymphoma
2. understand the new clinical staging systems for primary cutaneous lymphomas
3. select the optimal standard or investigative therapy for patients with a primary cutaneous lymphoma.

Description:
This session will review the most recent data in respect of proper diagnosis, staging and management of patients with a cutaneous lymphoma. The session will start with an overview of the ISCL/EORTC proposals for new clinical staging systems for mycosis fungoides/Sezary syndrome (MF/SS) and primary cutaneous lymphomas other than MF/SS. The EORTC consensus will be presented, recommendations for the treatment of MF/SS will be provided, and innovative therapies currently being investigated in clinical trials discussed. Finally, standard and new therapies for major types of cutaneous B-cell lymphomas will be presented.

10.15	S6.1	A new staging system for MF/SS. N. Pimpinelli (Florence, Italy)
10.30	S6.2	A new staging system for non-MF/SS primary cutaneous lymphomas. R. Willemze (Leiden, Netherlands)
10.45	S6.3	EORTC consensus guidelines for the treatment of MF/SS. S. Whittaker (London, UK)
11.00	S6.4	New treatment options in CTCL: Immunomodulating therapies and monoclonal antibodies. M. Bagot (Créteil, France)
11.15	S6.5	New systemic therapies in CTCL. R. Dummer (Zurich, Switzerland)
11.30	S6.6	Management of cutaneous B-cell lymphomas. L. Cerroni (Graz, Austria)

S7 - Advances in the Management of HIV Disease
Thursday, 17 May 2007
8.30 – 10.00  Hall O

Chair:  N.H. Brockmeyer (Bochum, Germany)
Co-Chairs:  A. Rieger (Vienna, Austria), M. Alsina Gibert (Barcelona, Spain)

Learning objectives:
After this session the attendee will:

1. have an overview of the epidemiology of HIV in Europe and opportunities of research in networks,
2. know about new treatment strategies for HIV infection,
3. have knowledge of the diagnosis and management of treatment-associated side effects,
4. know about the pathogenesis and treatment of Kaposi`s sarcoma,
5. be aware of approaches for the prevention and treatment of HPV-induced neoplasia.

Description:
The session will provide an overview of HIV infection in Europe and highlight opportunities for research in networks. The success achieved in the management of HIV infection and HIV-associated tumors will be discussed.
 
At the end of the session the attendees will be able to select the correct therapeutic regimen for each condition and inform the HIV-infected patient competently about therapy-associated side effects, immune reconstitution syndrome and HIV-associated tumors. The session will offer recommendations for the management of HIV-infected patients and summarize recent advances in this field.

8.30	S7.1	Advances in HIV therapy. R. Zangerle (Innsbruck, Austria)
8.48	S7.2	Cutaneous side effects and immunoreconstitution syndrome. A. Rieger (Vienna, Austria)
9.06	S7.3	Kaposi’s sarcoma. M. Alsina Gibert (Barcelona, Spain)
9.24	S7.4	HPV-associated cancer in HIV patients: Diagnosis and treatment. A. Kreuter (Bochum, Germany)
9.42	S7.5	National networks for improved scientific synergy in Europe. N.H. Brockmeyer (Bochum, Germany)

S8 - Teledermatology
Thursday, 17 May 2007
15.00 – 16.30  Hall N

Chair:  H.P. Soyer (Graz, Austria)
Co-Chairs:  S. Chimenti (Roma, Italy), G. Jemec (Roskilde, Denmark)

Learning objectives:
After this session, the attendee will:

1. appreciate the relevance of teledermatology as a communication tool,
2. realize the relevance of teledermatology as such,
3. understand how teledermatology could enhance the abilities and potential of the population in general.

Description:
This symposium will provide a basic overview of teledermatology and draw attention to successful teledermatology projects. In addition, best-practice models, specific websites and pilot projects on remote dermatology consultations will be presented, and the emerging field of mobile teledermatology will be discussed in the context of teleconsultation. This workshop is geared to all colleagues interested in teledermatology and the valuable opportunities resulting from the dynamic growth of information technology.

15.00	S8.1	Teledermatology in dermatology. L. Witkamp (Amsterdam, Netherlands)
15.20	S8.2	The Danish experience. G. Jemec (Roskilde, Denmark)
15.32	S8.3	Teledermatology in the army. I. Klaz (Tel Aviv, Israel)
15.44	S8.4	5 years of Iranderma. O. Zargari (Rasht, Iran)
15.56	S8.5	Mobile teledermatology. H.P. Soyer (Graz, Austria)
16.08	S8.6	Whither teledermatology? S. Chimenti (Roma, Italy)

S9 - Dermatosis in the Genital Area
Thursday, 17 May 2007
8:30 – 10:00  Hall N

Chairs: M. Pelisse (Paris, France)
Co-Chairs: D. Forsea (Bucharest, Romania), S. Neill (London, UK)

Learning objectives:
After this session the attendee will be able to:

1. diagnose the most frequent diseases of the vulva and the penis,
2. select the best treatments and be aware of recent therapies for some diseases.

Description:
Diseases of the vulva and the penis are still poorly known. However, many of them are easy to identify and treat. The genital mucosa may be affected by several types of dermatosis, the most common of these being lichen sclerosus. Every dermatologist must be able to recognize and treat this condition appropriately.
Erosive lesions of the penis are a common phenomenon. However, their etiology is frequently difficult to establish. Precancerous lesions have various clinical patterns which must be known in order to prevent invasive carcinoma.
New  therapies, particularly imiquimod, can be helpful in curing some precancerous lesions.

8.30	S9.1	The pathogenesis of lichen sclerosus: an update. F. Wojnarowska (Oxford, UK)
8.48	S9.2	Penile erosive lesions: diagnostic problems. C. Popescu (Bucharest, Romania)
9.01	S9.3	VIN current issues on diagnosis and treatment. S. Neill (London, UK)
9.19	S9.4	Paget’s disease a new treatment. M. Moyal-Barracco (Paris, France)
9.37	S9.5	Buschke-Lowenstein giant condyloma of the penis. D. Forsea (Bucharest, Romania)

S10 - Atopic Dermatitis in Children
Thursday, 17 May 2007
8:30 – 10:00  Hall A

Chair:  A. Giannetti (Modena, Italy)
Co-Chairs:  M.J. Cork (Sheffield, UK), T. Bieber (Bonn, Germany)

Learning objectives:
After this session the attendee will:

1. know about the genetic background of AD,
2. appreciate the value of diagnostic methods in AD,
3. have an updated view of the natural history of AD.

Description:
Atopic dermatitis (AD) is a common skin disease with a strong genetic background. Information about its pathogenesis has markedly enhanced our knowledge of many aspects of the disease. The influence of environmental factors in the pathogenesis of AD may be relevant. Its recognition should be strongly pursued. Testing should include allergy work-up (IgE-specific test and atopic patch test).  Early diagnosis of the skin and systemic complications such as infection, including S. aureus and Herpes simplex infections, are important aspects of this condition.

8.30	S10.1	Gene-environment interactions in atopic dermatitis: New treatment opportunities. M.J. Cork (Sheffield, UK)
8.48	S10.2	Improving the value of allergy testing in childhood atopic eczema with atopy patch tests? U. Darsow (Munich, Germany)
9.06	S10.3	Infectious complications of atopic dermatitis in children. A. Wollenberg (Munich, Germany)
9.24	S10.4	Relevance of food allergy in childhood atopic dermatitis. A. Giannetti (Modena, Italy)
9.42	S10.5	Atopic dermatitis in children: Quo vadis? T. Bieber (Bonn, Germany)

S11 - Atopic Dermatitis in Adults
Thursday, 17 May 2007
10.15 – 11.45  Hall A

Chair:  J. Ring (Munich, Germany)
Co-Chair(s):  L. Puig (Barcelona, Spain), J. Ronnevig (Oslo, Norway)

Learning objectives:
After these sessions the attendee will:

1. be aware of the differences between childhood and adult atopic eczema with regard to epidemiology, pathophysiology and clinical aspects,
2. learn about the role of triggering factors from the environment as well as from the skin surface in inciting flares,
3. be updated on preventive and therapeutic aspects of the management of adult atopic eczema.

Description:
Despite the widespread belief that atopic eczema is a childhood disease it is, in fact, a condition that may well affect adults. Contrary to the widespread notion that children grow out of eczema, 50-70% of affected children will still suffer from eczema in adulthood or acquire atopic eczema as adults. This symposium will focus on several aspects of adult atopic eczema, its pathophysiology and treatment.

10.15	S11.1	Atopy and the maturation of the immune system. J. Ring (Munich, Germany)
10.30	S11.2	Epidemiology of adult atopic eczema. M. Möhrenschlager (Munich, Germany)
10.45	S11.3	Contact dermatitis and atopic eczema in adults: occupational aspects. J. Lipozencic (Zagreb, Croatia)
11.00	S11.4	Role of superantigens in flares of atopic eczema. A. Alomar (Barcelona, Spain)
11.15	S11.5	Malassezia and adult atopic eczema. J. Faergemann (Göteborg, Sweden)
11.30	S11.6	Autoimmune phenomena in persistent atopic eczema. I. Mittermann (Vienna, Austria)

S12 - Botulinum Toxin: Use and Misuse
Saturday, 19 May 2007
8.30 – 10.00  Hall E

Chair:  D. Vochelle (Brussels, Belgium)
Co-Chairs:  C. Bayerl (Wiesbaden, Germany), P. Levy (Geneva, Switzerland):      

Learning objectives:
This session will familiarize the attendee with the main rules of botulinum injections:

1. Before injecting botulinum toxin the dermatologist must have comprehensive knowledge of the anatomy of the concerned muscles. Using slides, Lakhdar Belhaouari will demonstrate the exact targets of injection on facial dissections.
2. Botulinum toxin type A has now  been widely used  for more than 15 years in cosmetic indications such as facial wrinkles caused by repeated facial muscle contractions. Spectacular results have been achieved in the upper face, which remains the principal approved site for botulinum toxin in many countries. Christiane Bayerl will report her experience in this field. Approaching the patient, the technique of injection, and the choice of concentrations will be discussed.
3. In addition to Botox*( Allergan) and Dysport* (Ipsen), other botulinum toxin type A or B are, or will be, commercialized in several countries including Asia. Some of the substances are clandestinely sold on the web. Pierre André will talk about differences in the efficacy, power, the diffusion effect and duration of these toxins. He will also speak about the safety and production process of these substances.
4. Botulinum toxin injections are now administered in the lower portion of the face, namely the chin, the “marionette lines”, the mandible, the neck (platysma) and also the chest. Phillip Levy will tell us how we can model these areas and counteract aging of the skin ageing due to gravity. He will share his knowledge and experience about the choice of targets and the traps to avoid. 
5. A further major indication for the use of botulinum toxin is hyperhidrosis. Spectacular results have been achieved in the axilla, where the technique is easy to implement and  painless. With regard to other interesting areas such as the palms and the soles, Oliver Kreyden will demonstrate how a nerve block can be avoided by the use of a cryoanesthesia spray.
6. We know that no technique is devoid of side effects. Botulinum toxin type A might be associated with a few minor adverse events such as pain, headache or bruise. Accidents are rare, incidental, operator-dependant and always transient. Golden rules to avoid  ptosis, diplopia, or asymmetry of the smile shall be reiterated.

8.30	S12.1	Botulinum toxin type A: The prime requirement is profound knowledge of anatomy. L. Belhaouari (Toulouse, France)
8.45	S12.2	Botulinum toxin type A: My daily experience in the management of lines of the upper face. C. Bayerl (Wiesbaden, Germany)
9.00	S12.3	Are there any differences between botulinum toxins? P. André (Paris, France)
9.15	S12.4	Latest refinements concerning the lower face, the neck and the chest. P. Levy (Geneva, Switzerland)
9.30	S12.5	Botulinum toxin type A: Advanced indications in the management of hyperhidrosis. O. Kreyden (Basel, Switzerland)
9.45	S12.6	Some adverse events can occur... D. Vochelle (Brussels , Belgium)

S13 - Skin Fillers
Thursday, 17 May 2007
15.00 – 16.30  Hall F1

Chair:  P. André (Paris, France)
Co-chairs: I. Ghersetich (Florence, Italy), H. Kurwa (London, UK)

Learning objectives:
After the session the attendees will be aware of the main features of filling agents.

Description:
Many products have been launched for the treatment of wrinkles, folds and fine lines. There is a growing demand for volume. Specific products in this context will be described.
Two major classes of filling agents will be discussed;
Biodegradable
Non-biodegradable
Each has its benefits and drawbacks.
It is important to be aware of the adverse reactions of each product.
Histopathological aspects are now well known and may be used to prove the negative effect of any injected agent.
The efficacy of hyaluronan will be demonstrated by means of ultrasound technology.
At the end of the session the attendee will be aware of the risks and benefits of each type of filler.

15.00	S13.1	What’s new in biodegradable fillers? H. Kurwa (London, UK)
15.15	S13.2	What’s new in long-lasting fillers? E. Haneke (Freiburg, Germany)
15.30	S13.3	Histological aspects of fillers and their significances. L. Puig (Barcelona, Spain)
15.45	S13.4	What can we do about complications? P. Andre (Paris, France)
16.00	S13.5	Non-surgical face lift with polylactic acid. R. Serri, I. Ghersetich (Florence, Italy)
16.15	S13.6	Mesotherapy concerning facial and cervical “rejuvenation” with hyaluronan injections: an open comparative study with the help of ultrasound - is it a joke? D. Vochelle (Brussels, Belgium)

S14 - The Management of Hyperhidrosis
Thursday, 17 May 2007
8:30 – 10:00  Hall F2

Chair:  M. Neumann (Rotterdam, Netherlands)
Co-Chairs:  A. Campanati (Ancona, Italy), G. Kontochristopoulos (Athens, Greece)

Learning Objectives:
The speakers report their experience in the clinical and therapeutic management of severe forms of focal palmar and plantar idopatic hyperhidrosis.
Hyperhidrosis is a very common problem. Excessive hyperhidrosis leads to a degree of quality of life and in this session pathology, pathophysiology, impact for patients and therapeutical approaches will be discussed.

Description:
Focal idiopatic hyperhidrosis represents a very disabling condition with a great impact on patient’s life quality.
Treatment options lie on a continuum based on the severity of clinical situation and risk-benefits balance related to therapy. In general therapeutic approach for plantar and palmar hyperhidrosis starts with use of antiperspirants, followed by lontophoresis. Botulinum toxin type A, represents the second line treatment choice for non responder form of focal plantar and palmar hyperhidrosis. Surgical approach represents the ëxtrema ratio”therapeutic course and is represented by endoscopic thoracic sympathectomy.

8.30		Introduction. M. Neumann (Rotterdam, Netherlands)
8.35	S14.1	Palmar and plantar hyperhidrosis:therapeutic management. A. Campanati (Ancona, Italy)
8.52	S14.2	Treatment of hyperhidrosis in disorders, such as dyshidroticeczema, Darrier disease, Hailey-Hailey, pachyonychia, etc. S. Gregoriou (Athens, Greece)
9.09	S14.3	Purcutaneous retrodermal curettage for axillary hyperhidrosis? C. Rowland-Payne (London, UK)
9.26	S14.5	Surgical interventions for localized Hyperhidrosis. D. Trebing (Dessau, Germany)
9.43	S14.6	Botulinum toxin (type A) in axillary and palmoplantar Hyperhidrosis. G. Kontochristopoulos (Athens, Greece)

S15 - Psoriasis
Thursday, 17 May 2007
10.15 – 11.45  Hall F1

Chair:  M.A. De Rie (Amsterdam, Netherlands)
Co-Chairs:  L. Dubertret (Paris, France), R. Gniadecki (Copenhagen, Denmark)

Learning objectives:
After this session the attendee will:

1. realize that psoriasis is a systemic disease with important associated phenomena and co-morbidities,
2. understand the pathogenesis of psoriasis,
3. understand the place of traditional and new systemic therapies in psoriasis.

Description:
The objective of this session is to provide an update on disease associations and co-morbidities in psoriasis. The dermatologist must have this information in order to appreciate the fact that psoriasis is a systemic disease requiring systemic therapy. New insights into the pathogenesis of psoriasis will be presented. This will enable one to understand how new and traditional therapies work. The session will provide relevant information about traditional systemic therapies in this era of new biological therapies. Finally, an update on treatment modalities for psoriasis will be presented.

10.15		Introduction, M.A. De Rie (Amsterdam, Netherlands)
10.25	S15.1	Disease associations in psoriasis. U. Mrowietz (Kiel, Germany)
10.45	S15.2	Pathways and paradigms for psoriasis pathogenesis. C. Griffiths (Manchester, UK)
11.05	S15.3	Acitretine, methotrexate, cyclosporin in the era of biologicals. L. Dubertret (Paris, France)
11.25	S15.4	New drugs in psoriasis. R. Gniadecki (Copenhagen, Denmark)

S16 - Update on the Management of Melanoma
Friday, 18 May 2007
15.00 – 16.30  Hall F1

Chair:  H. Pehamberger (Vienna, Austria)
Co-Chairs:  E.B. Bröcker (Würzburg, Germany), J.L. Diaz-Perez (Bilbao, Spain)

Learning objectives:
After this session the attendee will be able to:

1. determine the indications for the management of melanoma,
2. select the appropriate immunotherapy based on the scientific background and clinical data,
3. be aware of treatment procedures for melanoma and their side effects.

Description:
The session will cover present knowledge on research, options, indications and risks and
benefits of current available therapeutic strategies in development.

15.00		Introduction. H. Pehamberger (Vienna, Austria)
15.05	S16.1	Tumor models mimicking melanoma patients. R. Kunstfeld (Vienna, Austria)
15.17	S16.2	Interferon treatment. C. Garbe (Tübingen, Germany)
15.29	S16.3	Interleukin II in melanoma therapy – Why and why not. J.L. Diaz-Pérez (Bilbao, Spain)
15.41	S16.4	Targeted therapy. H. Pehamberger (Vienna, Austria)
15.53	S16.5	Should we offer third-line therapies to melanoma patients? E.B. Bröcker (Würzburg, Germany)
16.05	S16.6	Impact of serum markers on therapeutic decisions. S. Ugurel (Mannheim, Germany)
16.17	S16.7	Selection of design, objectives and outcome measures for assessing new therapies in melanoma. J.J. Grob (Marseille, France)

S17 - Facial Dermatoses
Thursday, 17 May 2007
15.00 – 16.30  Hall H

Chair:  J. Pace (Naxxar, Malta)
Co-Chairs: G. Plewig (Munich, Germany), F. Powell (Dublin, Ireland)

Learning Objectives:
After this session attendee will:

1. know how facial dermatoses have been viewed and treated by our predecessors,
2. learn about modern concepts of rosacea and visual complications,
3. be aware of modern concepts of lupus erythematosus, its diagnosis, and management,
4. consider the possibility of leishmaniasis in obscure cases of “post-vacation ulceration”.

Description:
In this session Lawrence Parish will first address facial dermatoses as perceived by dermatologists in the past. Rosacea will then be discussed in depth by Frank Powell (Diagnostic criteria and epidemiology) and Gerd Plewig (Rosaces and the eye).The experience of the Warsaw Medical Academy on lupus erythematosus of the face will be presented by Maria Blaszczkyk-Kostanecka while Joseph Pace will close the session with a presentation on cutaneous leishmaniasis (post-vacation ulceration) - a disease that may be manifested several months after exposure to an endemic area.

15.00		Introduction. J. Pace (Naxxar, Malta)
15.05	S17.1	Facial dermatoses - historical aspects. L. Parish (Philadelphia, USA)
15.22	S17.2	Rosacea - Diagnostic criteria and epidemiology. F Powell (Dublin, Ireland)
15.39	S17.3	Rosacea and the eye. G. Plewig (Munich, Germany)
15.56	S17.4	Lupus erythematosus. M. Blaszczyk-Kostanecka, S. Jablonska (Warsaw, Poland)
16.13	S17.5	Post-vacation ulceration. J. Pace (Naxxar, Malta)

S18 - Skin Signs of Autoimmune Diseases
Friday, 18 May 2007
11.00 – 12.30  Hall N

Chair:  M. Meurer (Dresdeb, Germany) 
Co-Chairs:  C. Frances (Paris, France), M. Hertl (Marburg, Germany)

Learning objectives:
After this session the attendee will be able to:

1. diagnose multiorgan autoimmune disorders early,
2. recognize cutaneous manifestations of these disorders,
3. better understand the complex autoimmune pathomechanisms underlying systemic multiorgan autoimmune disease.

Description:
This section supplements other sessions of this EADV congress on autoimmune diseases of the skin by focusing on the involvement of the skin in systemic or multiorgan autoimmune disorders, their diagnosis and treatment. In addition, the speakers will present recent data on the autoimmune pathomechanisms underlying cutaneous as well as systemic manifestations and will share with the audience their experience concerning novel treatment modalities for these multiorgan autoimmune disorders.

11.00	S18.1	Skin manifestations of APS. C. Francés (Paris, France)
11.18	S18.2	Skin signs of ATD. A. Parodi (Genoa, Italy)
11.36	S18.3	Skin manifestations of systemic vasculitides including Wegener syndrome. M. Meurer (Dresden, Germany)
11.54	S18.4	Skin manifestations of relapsing polychondritis. M. Ryboyad (Paris, France)
12.12	S18.5	Skin manifestations in Sjoegren disease. M. Lecha, C.Herrero (Barcelona, Spain)

S19 - Hyperpigmentary Disorders
Friday, 18 May 2007
11.00 – 12.30  Hall I

Chair:  J.P. Ortonne (Nice, France)
Co-Chairs:  H. Shimizu (Sapporo, Japan), L.F. Xiang (Shanghai, China)

Learning objectives:
After this session the attendee will:

1. know about the different clinical phenotypes of unusual hyperpigmentary disorders,
2. be able to analyze the available treatments for hyperpigmentary disorders.

Description:
This symposium will provide insight into the pathogenesis, clinical aspects and treatment of common and uncommon hyperpigmentary disorders.

11.00	S19.1	Hypopigmented agents: biological, chemical and clinical aspects. M. Picardo (Rome, Italy)
11.18	S19.2	Chemical peeling in the treatment of melasma. L.F. Xiang (Shanghai, China)
11.36	S19.3	Prurigo pigmentosa. H. Shimizu (Sapporo, Japan)
11.54	S19.4	Idiopathic eruptive macular pigmentation. M. El Darouti (Cairo, Egypt)
12.13	S19.5	Recent advances in the pathogenesis of hypermelanoses. J.P. Ortonne (Nice, France)

S20 - Cosmetics in Dermatology
Friday, 18 May 2007
15.00 – 16.30  Hall K

Chair: A. Rougier (Asnières, France)
Co-Chair: E. Leitner (Vienna, Austria)

Learning objectives:
This session will highlight the use of cosmetics as an adjunctive measure to prevent, treat or accompany, and avoid relapse of some types of dermatosis.

Description:
It is time to accurately identify two fundamentally different fields in cosmetology: decorative and/ or protective cosmetology on one hand, and active cosmetology on the other.

In the case of active cosmetology, embellishment of the skin and its appearance is accomplished by improving its physiological state. It is now an established fact that cosmetics do, in fact, exert an effect on the lipid layer of the skin, skin hydration, stratum corneum barrier function, sebaceous and sudoral glands activities, pigmentation disorders, dermal components, epidermal and dermal cells activities, and prevention of damage from exposure to the sun.

An increasing number of cosmetic products are dedicated to dermatology. This session will focus on how cosmetics can help the dermatologist to prevent skin disorders, accompany treatment, or avoid relapses.

15.00	S20.1	Cosmetics in the management of acne. B. Dreno (Nantes, France)
15.18	S20.2	Cosmetics in the management of atopic dermatitis. C. Gelmetti (Milano, Italy)
15.36	S20.3	Broad-spectrum sunscreen for prevention of photo-Induced dermatosis. A. Rougier (Asnières, France)
15.54	S20.4	Corrective make-up in dermatology. A. Alomar (Barcelona Spain)
16.12	S20.5	Cosmetics in esthetic dermatology procedures. A. Fratila (Bonn, Germany)

S21 - Dermato-venerological Problems of Puberty
Saturday, 19 May 2007
13.00 – 14.30  Hall I

Chair:  C. Heller-Vitouch (Vienna, Austria)
Co-Chairs:  A. Ranki (Helsinki, Finland), C. Bodemer (Paris, France)

Description:

1. Adolescence is a period during which often appear systemic diseases. In particular, acrocyanosis is not an exceptional problem in female teenagers. It is also a perion during which therapeutic compliance is difficult. We wish to discuss certain particular aspects specific to this age
2. The lecture covers aspects of allergy in puberty with reference to an out-patient clinic in Vienna. Some basic considerations on allergy as seen from an immunological point of view are presented.
3. In dealing with STI in childhood, the physician bears a specific responsibility involving questions of jurisdiction and professional laws. Taking into consideration the age of the child, the sexually transmittable agent, and the location of the infection helps in assessing the possibility of sexual abuse. The presence of an STI may be the only indication of sexual abuse. The possibility of nonsexual transmission should be considered only if sexual abuse has been excluded.
4. Results of the Finnish STD sentinel surveillance network from 1996 to 2005 provide epidemiological data on STI’s, including HPV and HSV. Chlamydia, HPV and HSV were prevalent in young women <20 years of age. The prevalence of Chlamydia increased significantly in this age group. both in women and in men. Changes in risk-taking behavior, such as an increase in the number of annual partners and the consumption of alcohol, are issues of concern.
5. A large number of adolescents acquire an HPV infection when they start their sexual lives. Prophylactic immunization prior to that age will most likely prevent subsequent diseases as condylomata acuminata and cervical cancer. In some countries, the subject of vaccination against sexually transmittable agents gives rise to ethical discussion.

13.00	S21.1	Particular aspects of systemic diseases through adolescence. C. Bodemer (Paris, France)
13.15	S21.2	Allergy from childhood to adulthood. C. Ebner (Vienna, Austria)
13.30	S21.3	STI in prepubertal children – a practical approach. P. Kohl (Berlin, Germany)
13.45	S21.4	Recent trends of STIs in adolescents. E. Hiltunen-Back (Helsinki, Finland)
14.00	S21.5	Practical aspects of HPV infection in puberty. C. Heller-Vitouch (Vienna, Austria)
14.15		Discussion

S22 - Non-infectious Dermatoses with Severe Systemic Involvement  
Friday, 18 May 2007
15.00 – 16.30  Hall G

Chair:  L.E. French (Geneva, Switzerland)
Co-Chairs:  M. Binder (Vienna, Austria), P. Wolkenstein (Paris, France)

Learning Objectives:
After this session the attendee will:

1. know about the clinical presentation of important non-infectious dermatoses with severe systemic involvement,
2. be able to make an appropriate differential diagnosis and avoid common pitfalls,
3. be aware of the practical management and therapeutic options.

Description:
This symposium will provide an update on skin manifestations of 5 non-infectious dermatoses with severe systemic involvement. Experts in each field will focus on clinical aspects and cutaneous signs that allow rapid diagnosis, as well as provide a brief overview of the appropriate work-up and first-line approach to therapy.

15.00	S22.1	Eosinophilic dermatoses: Clinical and pathological diversity. S. Aractingi (Paris, France)
15.15	S22.2	Neutrophilic dermatosis with focus on Adamantiades-Behçet’s disease. C. Zouboulis (Dessau, Germany)
15.30	S22.3	Lupus erythematosus: when should we worry and how should we manage? R. Rondinone (Padova, Italy)
15.45	S22.4	Dermatomyositis: evaluation and management, R. Trüeb (Zurich, Switzerland)
16.00	S22.5	Severe cutaneous adverse drug reactions: Clinical features and risk factors. P. Wolkenstein (Créteil, France)
16.15		Discussion

S23 - Infectious Dermatoses with Severe Systemic Involvement
Friday, 18 May 2007
9.15 – 10.45  Hall M

Chair:  J. Peyrí (Barcelona, Spain)
Co-Chairs:  H. Schöfer (Frankfurt, Germany), N. Tsankov (Sofia, Bulgaria)

Learning objectives:
After this session the attendee will be able to:

1. recognize early clinical features of infectious dermatoses with systemic involvement or cutaneous manifestations as a main marker of severe infectious disease,
2. analyze the complex relationship between different cutaneous reactions due to infectious diseases and infectious dermatoses causing several systemic manifestations,
3. manage patients with life-threatening disease.

Description:
This symposium is designed to teach patterns of skin diseases seen in infectious processes of different kinds: viral, bacterial or mycobaterial. The complex diagnosis of manifestations in HIV and mycobacteria will be addressed. Infectious dermatoses are usually fairly simple to diagnose. However, in some cases the dermatologist is called upon to recognize the cutaneous manifestation as a clinical condition leading to severe problems. Early diagnosis may be a life-saving factor in cases of infectious fascitis. Various infectious agents are capable of inducing pathological process such as panniculitis or vasculitis.

9.15	S23.1	From Erysipelas to infectious fascitis. J. Revuz (Creteil, France)
9.30	S23.2	Drug hypersensitivity syndrome. N. Tsankov (Sofia, Bulgaria)
9.45	S23.3	Septic vasculitis. Y. Delgado (Madrid, Spain)
10.00	S23.4	Severe cutaneous complications in HIV infection. V. Piguet (Geneva, Switzerland)
10.15	S23.5	Leprosy: More than an infection. R. Anadolu-Brasie (Ankara, Turkey)
10.30	S23.6	Discussion

S24 - Laser for Vascular, Pigmentary and Hair Disorders
Thursday, 17 May 2007
8:30 – 10.00  Hall F1

Chair:  M. Landthaler (Regensburg, Germany)
Co-Chairs: A. Troilius (Malmö, Sweden), P. Calzavara-Pinton (Brescia, Italy)

Learning objectives:
At this session the attendee will be informed about:

1. the most important indications for laser therapy,
2. different lasers and IPL used in dermatology,
3. controversial indications such as melanocytic nevi, side effects and limitations.

Description:
Indications for laser therapy include vascular lesions (PWS, hemangiomas, leg veins), removal of tattoos, removal of unwanted hair and, recently, inflammatory skin diseases and vitiligo.

The following measures may be used: several different lasers, IPL, lasers for coagulation, vaporization and ablation of tissue, lasers for selective photothermolysis, and ‘anti-inflammatory’ lasers inducing T-cell apoptosis.

Several conditions can be treated with different lasers, but no laser is suitable for every indication. The aim of the session is to provide information about the broad spectrum of available lasers and their suitability for individual indications.

8.30	S24.1	Treatment of vascular lesions. M. Landthaler (Regensburg,Germany)
8.45	S24.2	Removal of tattoos. A. Troilius (Malmö, Sweden)
9.00	S24.3	Removal of unwanted hair. M. Adatto (Geneva, Switzerland)
9.15	S24.4	Treatment of pigmented lesions. I. de Felipe (Madrid, Spain)
9.30	S24.5	Laser therapy of vitiligo. M. Gold (Nashville, USA)
9.45	S24.6	Indications for IPL systems. P. Bjerring (Aarhus, Denmark)

S25 - Evidence-based versus Eminence-based Dermatology
Thursday, 17 May 2007
15.00 – 16.30  Hall F2

Chair:  T. Diepgen (Heidelberg, Germany)
Co-Chairs:  L. Naldi (Bergamo, Italy), O. Chosidow (Paris, France)

Learning objectives:
After this session attendee will be able to:

1. respond to significant clinical questions based on the PICO approach (population, intervention, comparison, outcome),
2. identify factors that may hinder the development of research activities on important clinical questions such as rare disorders,
3. understand the relevance and limitations of an evidence-based approach in the real world where research questions are intermingled with economical interests and limited resources.

Description:
Evidence-based medicine differs from the traditional approach to health care in that, in addition to relying on clinical experience, expert opinion, and knowledge of pathophysiology for clinical decision-making, clinicians identify important knowledge gaps and information needs, formulate answerable questions, identify potentially relevant research, assess the validity of evidence and results, and apply research evidence to individual patients in a way that takes into account the patients' particular experiences, expectations, and values. The principles of the evidence-based approach will be presented with special reference to important skin disorders such as atopic dermatitis and psoriasis. Special problems relating to the evidence-based approach will be discussed in selected orphan areas such as genodermatosis. The limitations of the evidence-based approach in the real world, where clinical questions are intermingled with economical interests and limited resources will be analyzed, and the importance of independent collaborative clinical research programs emphasized.

15.00	S25.1	Priority definitions for clinical research in dermatology. C. Paul (Toulouse, France)
15.18	S25.2	Experience with research activities on important clinical questions: the case of severe drug adverse reactions. A. Sidoroff (Innsbruck, Austria)
15.36	S25.3	Research and clinical networks. The European experience. L. Naldi (Bergamo, Italy)
15.54	S25.4	Future perspective for independent clinical research in dermatology. T. Diepgen (Heidelberg, Germany)
16.12	S25.5	Interactive discussion

S26 - Non-surgical Treatments of Non-melanoma Skin Cancer
Saturday, 19 May 2007
10.15 – 11.45  Hall B

Chair:  B. Giannotti (Florence, Italy)
Co-Chairs:  L. Braathen (Bern, Switzerland), O. Larkö (Göteborg, Sweden)

Learning objectives:
After this session the attendee will:

1. have extended his/her knowledge of the rationale for non-surgical treatment of non-melanoma skin cancer (NMSC) for the purpose of better treatment of this condition,
2. be acquainted with old and new methods of treatment,
3. be able to select the most appropriate treatment in individual cases.

Description:
The different techniques of non-surgical treatment of NMSC will be examined, particularly recent immunological approaches, in order to tailor the treatment for individual patients, also taking into account the condition of the patient and/or the location of the tumor. Finally, based on an analysis of epidemiological data, suggestions to improve primary prevention of actic keratosis and basal/squamous cell carcinoma will be presented.

10.15	S26.1	Epidemiology of non-melanoma skin cancer. B. Giannotti, (Florence, Italy)
10.30	S26.2	Radiotherapy. L. Andreassi (Siena, Italy)
10.45	S26.3	5 FU and imiquimod. O. Larkö (Göteborg, Sweden)
11.00	S26.4	Interferon treatment. S. Bϋchner (Basel, Switzerland)
11.15	S26.5	Cryotherapy. R. Suhonen (Mikkeli, Finland)
11.30	S26.6	Photodynamic therapy. L.R. Braathen (Bern, Switzerland)

S27 - Important Harmful or Unaffordable Practices and their Dermatological Management
Friday, 18 May 2007
9.15 – 10.45  Hall I

Chair:  T.J. Ryan (Oxford, UK)
Co-Chairs: A. Mahe (Libreville, Gabon), B. Naafs (Munnekeburen, Netherlands)

Learning Objectives:
After this session the attendee will be able to: 

1. understand an extended role of dermatology,
2. appreciate the need for resources in impoverished regions,
3. appreciate certain strategies to alleviate poverty through dermatology.

Description:
This session focusing on certain acquired bad practices will describe major problems in the management of skin diseases with a view to enhancing the reputation of our profession with agencies of the United Nations.

9.15	S27.1	High technology when low technology will do. T.J. Ryan (Oxford, UK)
9.30	S27.2	Female genital mutilation. A. Morone (Rome, Italy)
9.45	S27.3	Manipulating skin color A. Mahe (Libreville, Gabon)
10.00	S27.4	Imported harmful or unaffordable practices and their management. B. Naafs (Munnekeburen, Netherlands)
10.15	S27.5	Solving harmful or unaffordable practice by integrating traditional medicine with “Western” medicine. S.R. Narahari (Kerala, India)
10.30		Discussion

S28 - What the History of Dermatovenerology can teach Today's Dermatovenerologist
Friday, 18 May 2007
11.00 – 12.30  Hall L

Chair:  K. Holubar (Vienna, Austria)
Co-Chairs: P. Emmanouil (Athens, Greece), D. Wallach (Paris, France)

Description:
In accordance with the regulations of the EADV we attempted to involve as many countries as possible in this framework. We asked for contributions from all of Austria’s neighboring countries, and let the contributors decide about the individual topics.

We shall present various aspects of the subject from these countries. Local, regional and national perspectives will give rise to a large spectrum of historical views. In this regard, the session in Vienna will differ from previous ones. At this session the subject will be presented as a general topic.

11.00	S28.1	Topical treatment or systemic treatment: What does the history of atopic dermatitis teach us? G. Tilles, D. Wallach, A. Taïeb: (Paris and Bordeaux, France)
11.10	S28.2	If they knew the history they would not wander around: The misconceptions of Mal de Meleda in the first half of the 20th century. S. Fatović-Ferenčić (Zagreb, Croatia)
11.20	S28.3	Mosaics from Hungarian dermatology. S. Karpáti (Budapest, Hungary)
11.30	S28.4	Dermatovenereology in Padova, D. Linder (Padova, Italy)
11.40	S28.5	Philipp Joseph Pick and Prague dermatology. P. Arenberger (Prague, Czech Republic)
11.50	S28.6	Innovations in Dermatology and Venereology from Dresden. S. Scholz (Wiener Neustadt, Austria)
12.00	S28.7	150 Years of dermatovenereology in Slovenia. M. Potocnik (Ljubljana, Slovenia)
12.10	S28.8	History of dermatology in Iran. F. Handjani (Shiraz, Iran)
12.20	S28.9	History of the development of the Wassermann-Neisser-Bruck Reaction. R. Bialynicki-Birula (Wroclaw, Poland)

S29 - The Aging Skin - Structural and Functional Changes
Friday, 18 May 2007
15.00 – 16.30  Hall F2

Chair:  K. Scharffetter-Kochanek (Ulm, Germany)
Co-Chairs: B. Gilchrest (Boston, USA), J.L. Leveque (Clichy, France)

Learning objectives:

1. How does skin aging occur, which factors drive it?
2. How can we assess skin aging?
3. How can we treat and prevent skin aging?
4. What can we learn from skin aging for the aging of other organs?

Description:
Aging of the skin has fascinated researchers and clinicians for decades. In addition to the ultimate goal of preventing wrinkles, the extensive interest in the subject is also due to the fact that the skin is an excellent and accessible model organ, allowing the study of intrinsic and extrinsic factors that jointly contribute to the complex phenomenon of aging.

This workshop concentrates on basic aspects of skin aging, including the imbalance towards enhanced proteolysis and cellular changes in the aging skin, as well as the endocrine mechanisms of aging. There will be a short introduction on how to assess skin aging, which is a prerequisite to monitor preventive and therapeutic agents. We will summarize new data on anti-aging therapy including an interesting study on photodynamic therapy, botox fillers and retinoids in the prevention and treatment of aging and photoaging.

Basic principles underlying skin aging were shown to be of general relevance for common degenerative diseases such as osteoarthritis, osteoporosis, arteriosclerosis and neoplastic disorders, thus making skin aging a highly relevant subject in science as well as clinical practice.

15.00		Introductory remarks. J.L. Leveque (Clichy, France)
15.05	S29.1	Mechanisms of aging and relevance for practice. B. Gilchrest (Boston, USA)
15.25	S29.2	How to deal with photodamage from botox fillers. M. Podda (Frankfurt, Germany)
15.45	S29.3	Endocrine mechanisms of aging. C. Zouboulis (Dessau, Germany)
16.05	S29.4	Retinoids in prevention and therapy of photoaging. S. Kang (Michigan, USA)
16.25		Perspectives. K. Scharffetter-Kochanek (Ulm, Germany)

S30 - Dermatology in China
Saturday, 19 May 2007
8.30 – 10.00  Hall N & O

Chair:  X. Zhu (Beijing, China)
Co-Chairs:  J. Sun (Beijing, China), Z. Zheng, (Shanghai, China)

Learning objectives:
This session will provide the attendee with:

1. a general introduction to dermatology in China,
2. an overview of psoriasis, vitiligo and the treatment of fungal infections in China,
3. an introduction to traditional Chinese medicine.

Description:
Dermatology is a booming medical discipline in China. In this session, five speakers from four leading dermatology institutes or medical universities will give an overview of dermatology and dermatopathology as well as traditional Chinese medicine in China. The speakers will also discuss the incidence, diagnosis, therapy and recent achievements in psoriasis, mycology and vitiligo, focusing on their experience in China.

8.30	S30.1	Introduction to Dermatology in China. X. Zhu (Beijing, China)
8.45	S30.2	Psoriasis in China. Z. Zheng  (Shanghai, China)
9.00	S30.3	Dermatopathology in China. J. Sun (Beijing, China)
9.15	S30.4	Mycology in China. R. Li (China)
9.30	S30.5	The treatment of vitiligo in China. F. Xiang (Shanghai, China)
9.45	S30.6	Traditional Chinese medicine in China. P. Song (China)

S31 - Rare Neoplasms of the Skin
Friday, 18 May 2007
9.15 – 10.45  Hall H

Chair: H. Kerl (Graz, Austria )
Co-Chairs: J. Langtry (Newcastle upon Tyne, UK), H. Kutzner (Friedrichshafen, Germany )

Learning objectives:
After this session the attendee will be able to:

1. recognize rare tumors of the skin and consider the unconventional in their differential diagnosis, 
2. integrate pathological features and modern diagnostic tests in clinical practice, 
3. use the acquired knowledge for a modern therapeutic approach.

Description:
Rare neoplasms of the skin are a most interesting and challenging subject in cutaneous oncology. Presentations, including lymphoma variants, vascular skin tumors, atypical melanocytic proliferations, and other selected areas will be addressed, and a wide spectrum of questions concerning diagnosis, new molecular investigations, pathogenesis, and therapy shall be covered.

9.15	S31.1	Variants of lymphoid proliferations. L. Cerroni (Graz, Austria)
9.33	S31.2	Surgery of dermatofibrosarcoma protuberans and other unusual skin tumors. J. Langtry (Newcastle upon Tyne, UK)
9.51	S31.3	Vascular neoplasms. H. Kutzner (Friedrichshafen, Germany)
10.09	S31.4	Clinico-pathologic conference: Diagnostically challenging presentations. P. Romanelli (Miami, USA), H. Kerl (Graz, Austria)

S32 - Acne
Saturday, 19 May 2007 
10.15 – 11.45  Hall E

Chair:  A. Katsambas (Athens, Greece)
Co-Chairs:  H. Gollnick (Magdeburg, Germany), L. Scerri (Floriana, Malta)

Learning objectives:
After this session the attendee will:

1. have an update on existing treatments,
2. be informed about current laboratory work on the subject of acne therapy,
3. have information about innovations in acne therapy.

Description:
The main purpose of the symposium is to inform the attendee about what is new and what is in the pipeline for acne treatment. The very important issue of diet and acne as well as new insights into the activity of azelaic acid will be covered. Systemic treatment, which is the principal therapy for moderate to severe acne, will be analyzed. Pitfalls in everyday management of the disease will be discussed. Finally, the participants will acquire knowledge about experimental acne treatment and the innovations planned for the next decade.

10.15	S32.1	What's new in therapy and in the pipeline for acne? H. Gollnick (Magdeburg, Germany)
10.30	S32.2	Diet and acne. B. Dreno (Nantes, France)
10.45	S32.3	New insights on the activity of azelaic acid in acne. M. Picardo (Rome, Italy)
11.00	S32.4	Acne: Systemic Treatment. A. Katsambas (Athens, Greece)
11.15	S32.5	Antibiotic resistance in acne: Is it clinically relevant? L. Scerri (Floriana, Malta)
11.30	S32.6	Experimental acne treatments: Innovations for clinical use in the next decade. C. Zouboulis (Dresden, Germany)

S33 - Nail Diseases
Saturday, 19 May 2007
8.30 – 10.00  Hall L & M

Chair:  E. Haneke (Freiburg, Germany)
Co-Chairs:  B. Richert (Liège, Belgium), D. Rigopoulos (Athens, Greece)

Learning objectives:
After this session the attendee will be able to:

1. treat the ingrowing toenail, perform nail avulsion, and remove nail melanoma accurately,
2. anticipate potential complications in nail surgery and treat them,
3. view onychomycosis and inflammatory nail diseases in a new way and select the right therapy.

Description:
This session, which will be devoted to nails, will cover three main fields: surgery, onychomycosis and inflammatory nail disorders.

Avulsion of the nail is a routine procedure in nail surgery. It allows visibility under the nail plate and is also part of the treatment of onychomycosis. An ingrowing toenail is a painful condition that requires surgical treatment in most instances. Being less aggressive in nail surgery reduces the risk of complications. Tips on the treatment of the ingrowing toenail as well as a technique to minimize trauma during avulsion will be outlined. Surgery of nail melanoma will be discussed. As the nail surgeon should be aware of potential complications, special attention will be given to their occurrence and the treatment options.

New insights into the pathogenesis of onychomycosis may help to understand and treat it better.
New techniques for the evaluation of inflammatory nail disorders shall be addressed.   

8.30	S33.1	Pearls in treating ingrown toenails. R. Daniel (Jackson, USA)
8.45	S33.2	Trap door avulsion minimizing trauma in nail surgery. D. De Berker (Bristol, United Kingdom)
9.00	S33.3	Subungual acral lentiginous melanoma surgery. M. Podda (Frankfurt, Germany)
9.15	S33.4	Complications in nail surgery. M. Dahdah (New York, USA)
9.30	S33.5	Should we teach onychomycosis in a new way? R. Baran (Cannes, France)
9.45	S33.6	Videomicroscopy of inflammatory nail disorders. M. Iorizzo (Bologna, Italy)

S34 - Disorders of the Hair Follicles and Scalp
Saturday, 19 May 2007
8.30 – 10.00  Hall I

Chairs:  A. Tosti (Bologna, Italy)
Co-Chair: U. Blume-Peyjtavi (Berlin, Germany)

Learning objectives:
After this session the attendee will be able to:

1. select the most appropriate method to evaluate hair growth and hair density.,
2. manage patients with genetic hair disorders,
3. identify which drugs and toxins can be analyzed in hair samples.

Description:
This session will first discuss methods to demonstrate the efficacy of hair growth promoters and what can be done to control the large hair growth market.

One lecture will be devoted to normality at different ages and will discuss hair loss and hair density in normal children, adults and the elderly.

Dermoscopy is a new non-invasive tool that may be very useful in the differential diagnosis of alopecia and scalp disorders. The attendee will be able to appreciate the use of this technique in diagnosing some difficult cases.

New genetic hair disorders will be presented.

8.30	S34.1	What's new in genetic hair disorders. A.Zlotogorski (Israel)
8.50	S34.2	“Hair normality”. A. Rebora (Genoa, Italy)
9.10	S34.4	Hair and nail in forensic medicine. R. Daniel III (USA)
9.30	S34.5	Scalp dermoscopy. A. Tosti (Bologna, Italy)

S35 - Diagnosis and Management of Vasculitis
Friday, 18 May 2007
9.15 – 10.45  Hall N

Chair:  N. Sepp (Innsbruck, Austria)
Co-chair(s):  D. Sotiriadis (Thessaloniki, Greece), C. Sunderkötter (Münster, Germany)

Description:
Vasculitis is an inflammation in which the primary event is damage of the vessel wall secondary to leukocytes. Leukocytoclastic vasculitis (LcV) involves the post-capillary venules. Vasculitis is due to pathomechanisms in addition to those of acute inflammation, which result in the damage of vessel walls.

LcV may share clinical and histological features with neutrophilic vascular (non-vasculitic) dermatoses. However, one needs to identify the different pathomechanisms associated with differences in organ involvement, the underlying disease, and its management. 

LcV on the skin may be limited to the skin, but may also involve systemic organs such as the kidney, intestine or CNS. It may present as an initial sign of ANCA-associated systemic vasculitis. Therefore, it is important to apply procedures that help to identify serious forms of vasculitis, and also not to over-treat cutaneous LcV.

9.15	S35.1	Clinical signs of vasculitis. N. Sepp (Innsbruck, Austria)
9.37	S35.2	Laboratory values and vasculitis. D. Sotiriadis (Thessaloniki, Greece)
10.00	S35.3	Infections and vasculitis. C. Sunderkötter (Münster, Germany)
10.22	S35.4	Therapy of vasculitis with clinical cases. N. Sepp, C. Sotiriadis, C. Sunderkötter

S36 - Skin and the Psyche
Saturday, 19 May 2007
10.15 – 11.45  Hall L & M

Chair:  F. Poot (Brussels, Belgium) 
Co-Chairs: U. Gieler (Giessen, Germany), A. Zalewska (Lodtz, Poland)

Learning objectives:
After this session the attendee will be able to:

1. screen for mental disorders associated with chronic skin disease,
2. understand the burden of chronic skin diseases, 
3. improve the management of  patients and patients’ families with chronic skin diseases.

Description:
In the management of patients with a chronic skin disease, the dermatologist encounters various problems. First of all, as dermatologists will be unable to cure the patients, they have to deal with their own feelings of inadequacy and limited competence. They also have to support the patients and help them to cope effectively with the disease. Finally, the dermatologist has to deal with the patients’ families – which may prove difficult in some instances – or handle a part of the patients’ problems.

Biopsychosocial understanding will help both patients and dermatologists. Moreover, it will have a positive effect on adherence behavior and the course of disease as well as the outcome of treatment.

10.15	S36.1	The interface of mental disorders in dermatology patients and chronicity. M. Musalek (Vienna, Austria)
10.30	S36.2	The families, the dermatologist and the chronic patient. F. Poot (Brussels, Belgium)
10.45	S36.3	Clinimetrics and psychometrics in the management of chronic disease. D. Linder (Padova, Italy)
11.00	S36.4	Relevance and applications of quality of life assessment in clinical practice. J. de Korte (Amsterdam, Netherlands)
11.15	S36.5	Adjustment to a chronic disease in psoriatic patients. A. Zalewska (Lodtz, Poland)
11.30	S36.6	Psychosocial management of atopic dermatitis. U. Gieler (Giessen, Germany)

S37 - Vitiligo and Hypopigmentation
Saturday, 19 May 2007
10.15 – 11.45  Hall H

Chair:  M. Picardo (Rome, Italy)
Co-Chairs:  K. Schallreuter (Bradford, UK), J. Lambert (Ghent, Belgium)

Learning objectives:
After this session the attendee will:

1. have in-depth knowledge of immunological and non-immunological mechanisms, focusing on the key role of oxidative stress in the pathogenesis of vitiligo,
2. learn about therapies currently in use and future trends,
3. be informed about the aims and achievements of the Vitiligo European Taskforce (VETF).

Description:
Vitiligo is a disease whose pathogenesis is poorly understood. As a result, its treatment is only partially satisfactory.
This session will review immunological and non-immunological mechanisms, focusing on oxidative stress as the basis of the disease. An appraisal of therapies currently in use and future treatments will be presented. The session will outline the objectives, achievements and work in progress of a Vitiligo European Taskforce set up in 2003. To date, the VETF has designed and validated an evaluation sheet to assess the staging, spread and extent of the disease. It has been tested in 11 European centers and could be easily handled in clinical practice. Future plans and goals will be discussed.

10.15	S37.1	Non-immunological mechanisms in the pathogenesis of Vitiligo: An overview, M. Picardo (Rome, Italy)
10.31	S37.2	Hydrogen peroxide and the skin. K. Schallreuter (Bradford, UK)
10.47	S37.3	Vitiligo from an immunologic point of view. J. Lambert (Ghent, Belgium)
11.03	S37.4	Vitiligo European Taskforce (VETF): Goals and achievements. A. Taïeb (Bordeaux, France)
11.19	S37.5	Treatment of vitiligo - current options and future directions. M. Böhm (Münster, Germany)

S38 - Human Papillomaviruses
Saturday, 19 May 2007
10.15 – 11.45  Hall I

Chair:  R. Kirnbauer (Vienna, Austria)
Co-Chairs:  C. Lacey (York, UK), A. Stratigos (Athens, Greece)

Learning objectives:
After this session the attendee will be able to:

1. clinically diagnose HPV-induced diseases of the skin and the ano-genital mucosa,
2. manage patients and interpret the results of HPV testing and histology,
3. develop appropriate treatment strategies for the immunocompetent or –suppressed patient, and counsel patients on HPV vaccination.

Description:
This symposium will outline the investigation and clinical management of patients with HPV-induced diseases of the skin and the mucosa. Novel HPV types and their possible relationship with skin diseases including non-melanoma skin cancer (NMSC) will be discussed. Participants will learn to develop custom-tailored strategies for immunocompetent and immunosuppressed (including HIV-infected) patients. The advantages of novel and conventional treatments will be compared, emphasizing specific anatomical locations, histology, and the results of HPV testing. Finally, a recent FDA-licensed prophylactic HPV6, 11, 16, 18 vaccine will be introduced. The session will suggest how patients should be advised about this upcoming vaccine and how one should discuss with patients unresolved issues such as the duration of protection, vaccination of boys, and cross-protection for related high-risk HPV types.

10.15	S38.1	Novel aspects of HPV in skin diseases. A. Stratigos (Athens, Greece)
10.30	S38.2	HPV infection in the immunocompromised host. E. Stockfleth (Berlin, Germany)
10.45	S38.3	Novel Treatment Strategies for Genital Warts and Genital Intra-epithelial Neoplasia. C. Lacey (York, UK)
11.00	S38.4	Current status and unresolved issues of HPV vaccination. R. Kirnbauer (Vienna, Austria)
11.15	S38.5	Anal HPV infection and cancer – an emerging problem. A. Salat (Vienna, Austria)
11.30		Discussion

S39 - Lupus Erythematosus
Thursday, 17 May 2007
15.00 – 16.30  Hall O

Chair:  F. Wojnarowska (Oxford, UK)
Co-Chair(s):  A. Kuhn (Düsseldorf, Germany), S. Krueger-Krasagakis (Thessaloniki, Greece)

Learning Objectives:
After this session the attendee will be able to:

1. recognize cutaneous manifestations of lupus,
2. address the specific problems of lupus in women,
3. appreciate new therapies.

Description:
This session will describe and classify cutaneous manifestations of lupus including vasculitis, and will reinforce this learning with a clinical quiz. There will be significant emphasis on management, including the specific problems of lupus in women and the neonate. There will be an update on management including the use of biologics and other novel approaches.  Recent findings on the lupus band will be presented.

One of the purposes of this session is to make the clinician more confident about the diagnosis and management of this condition.

15.00		Introduction and welcome. F. Wojnarowska (Oxford, UK)
15.05	S39.1	Classification and clinical manifestations of cutaneous lupus erythematosus. A. Kuhn (Düsseldorf, Germany)
15.20	S39.2	Vasculitic manifestations of lupus. S. Krueger-Krasagakis (Heraklion, Greece)
15.30	S39.3	Specific problems in the management of female LE. E. Aberer (Graz, Austria)
15.40	S39.4	Lupus and pregnancy. F. Wojnarowska (Oxford, UK)
15.50	S39.5	Topical treatments for cutaneous lupus erythematosus: novel aspects. F. Nyberg (Stockholm, Sweden)
16.00	S39.6	Biologics and anti-cytokine therapy in the treatment of LE. M. Aringer (Vienna, Austria)
16.10	S39.7	The lupus band revisited. A. Alahlafi (Al Baida, Libya)
16.20		Discussion

S40 - Dermatology in Ethnic Skin
Saturday, 19 May 2007
8.30 – 10.00  Hall H

Chair:  M. Verschoore (Asnières, France)
Co-Chairs:  M. Amer (Cairo, Egypt), E. Higgins (London, UK)

Learning objectives:
After this session the attendee will be able to:

1. better appreciate physiological differences in skin, based on ethnic origin,
2. approach different diseases in Asian, black or Mediterranean populations,
3. understand the characteristics of black skin disorders after migration of Africans to the UK.

Description:
In the last ten years, our comprehension of differences in skin function and physiology across ethnic groups has been significantly enhanced. We are facing an increase in the migration of different populations from and to several parts of the world. In addition, the demography of oriental and black skin population has markedly changed in the last 50 years and will continue to do so in the future. Thus, any description of healthy skin or skin diseases must now systematically consider the main ethnic skin types: Caucasian, Asian, African, Latino and Indian. The present session will focus on recent advances in ethnic skin research with particular focus on black skin. It will also cover the skin allergy profiles of Caucasian and Asian populations for contact dermatitis. A special subject of interest will be dermatological conditions in Egypt and the specific features and epidemiology of melanoma in Togo. Finally, black skin dermatology is also specific when black skin Africans and Caribbeans migrate to a different climatic and cultural environment such as that in the United Kingdom.

8.30	S40.1	Update on black skin research. V. Holloway (Chicago, USA)
8.48	S40.2	Contact dermatitis in China. W.X. Min (Shanghai, China)
9.06	S40.3	Egyptian pattern of skin diseases. M. Amer (Cairo, Egypt)
9.24	S40.4	Dermatology practice of black African patients in the UK. E. Higgins (London, UK)
9.42		Discussion

S41 - ESDR Symposium
Friday, 18 May 2007
15.00 – 16.30  Hall N

Chair:  M.F. Jonkman (Groningen, Netherlands)
Co-Chair:  P. Wolf (Graz, Austria)

Learning objectives:
After this session the attendee will:

1. know about new advances in dermatological research,
2. foster his/her enthusiasm for dermatology and the skin.

Description:
The session will outline recent advances in our comprehension of the skin. The focus of the session will be translational research. Participants of the symposium will learn how the skin and heart are linked by sharing the same desmosome components. Subsequently, molecular mechanisms of viral synapse formation will be discussed; these provide a fascinating insight into how pathogens subvert immune cell communication programs and achieve viral spread. New insights into the role of apoptosis in the pathomechanism of acantholysis in pemphigus will be presented. Gene expression studies suggest that in the future we may develop new diagnostic and prognostic tools for lymphoma and identify subsets of patients who would benefit from more specific treatment protocols. Finally, the effects on UV light and the migration of UV light on dendritic cells will be addressed.

15.00	S41.1	The link between skin and heart: cardiocutaneous genetic syndromes. M.F. Jonkman (Groningen, Netherlands)
15.18	S41.2	Dangerous liaisons with a virus. V. Piguet (Geneva, Switzerland)
15.36	S41.3	First die and than let loose: the role of apoptosis in pemphigus. C. Pincelli (Modena, Italy)
15.54	S41.4	Epidermotropic T-cell lymphomas as models for tumour progression. M. Bagot (Créteil, France)
16.12	S41.5	Sunseekers: the Migration of Cells after Light Exposure. P. Wolf (Graz, Austria)

S42 - Tropical Dermatology
Saturday, 19 May 2007
13.00 – 14.30  Hall H

Chair:  P. R. Cunha (Jundiaí, Brazil)
Co-Chair:  M. Alchorne (São Paulo, Brazil), M.E. Massara Café (Belo Horizonte, Brazil)

Learning Objectives:
Following this session, the attendee will be able to:

1. Discuss common tropical diseases and their critical importance world-wide;
2. Be informed about what is new in Tropical Dermatosis, such as Subcutaneous Mycoses, Endemic Penphigus Foliaceus, Mucocutaneous Leishmaniasis, Leprosy and Cutaneous Tuberculosis;
3. Exchange international experience.

Despription:
We intend to discuss about the most frequent groups of Tropical Cutaneous Diseases, which are increasing their frequency nowadays.

As more than 50% of the whole world population live in the tropic and sub-tropic areas and as the tropical dermatosis are a health problem in more then a hundred countries with population of individuals who don’t have access to health care, those illnesses are of interest not only for dermatologists of those areas but also to practitioners of any country that deals with foreign and travelling patients. Practitioners of practically all countries of the world will possibly one day face those diseases.

All the speakers have wide experience with these diseases and our objective is to explore, based on the recent advances, the current strategies in clinical and laboratorial diagnosis, prevention and therapeutic aspects.

13.00		Welcome & Introduction. P.R. Cunha (Jundiaí, Brazil)
13.05	S42.1	Tropical Skin Problems in Their International Relevance.O. Lupi ( Rio de Janeiro, Brazil)
13.20	S42.2	Subcutaneous Mycosis – What’s new? S. Marques (São Paulo, Brazil)
13.35	S42.3	Endemic Pemphigus Foliaceus – an Update. P.R. Cunha (Jundiaí, Brazil)
13.50	S42.4	Mucocutaneous Leishmaniasis – New Developments in Epidemiology, Diagnosis and Treatment. A. Alchorne (São Paulo, Brazil)
14.05	S42.5	A Practical Diagnostic Approach to Patients With Leprosy and Cutaneous Tuberculosis.L. Azulay (Rio de Janeiro, Brazil)
14.20		Questions & answers

S43 - Dermatology in India
Saturday, 19 May 2007
10.15 – 11.45  Hall N & O

Chair:  S.Verma (Baroda, India)
Co-Chairs:  V. Mendiratta (New Delhi, India), N. Madnani (Mumbai, India)

Following this session the attendee will be able to

1. Appreciate the magnitude and diversity of Clinical Dermatology in India.
2. Get an insight into not just Indian but South Asian Dermatology.
3. Get an Insider’s perspective of South Asian Dermatology and its clinical nuances.

Description:
India, with a staggering 1.1 billion population has over 5000 dermatologists registered in its national association. Its annual meetings attracts over 4000 attendees each year and is therefore known as one of the largest attended dermatology conferences in the world after those of  AAD and EADV.

The session aims at giving a comprehensive understanding of practice of dermatology in a resource poor setting. It is, in fact, a prototype of dermatology practice in developing nations of South Asia with all their uniqueness, effects of cultural diversity and the relative lack of funding and awareness. The audience also gets the unique experience of seeing and hearing about some of the diseases that they have only read about and that are seen in India in abundance.

10.15	S43.1	A Phototour of Dermatology in India. S.Verma (Baroda, India)
10.30	S43.2	Dermatologic Teaching in India. M. Ramam (New Delhi, India)
10.40	S43.4	Common Cutaneous Infections in India. B. Shah (Ahmedabad, India)
10.55	S43.5	Pediatric Dermatology- An Indian Scenario. V. Mendiratta (New Delhi, India)
11.10	S43.6	Pigmentary Disorders-Indian clinicocultural perspective. A.J. Kanwar (Chandigarh, India)
11.25	S43.5	Cosmetic Dermatology and Dermatologic Surgery- An Indian look. N.G. Patwardhan (Pune, India)

S44 - Skin Diseases in Africa
Saturday, 19 May 2007
13.00 – 14.30  Hall N & O

Chairs:  C.E. Orfanos (Berlin, Germany)
Co-Chair:  A. Morrone (Rome, Italy)
 
Learning Objectives:
Following this session, the attendee will be able to:

1. feel more familiar with skin infections and other diseases that commonly occur in populations with pigmented skin in African countries.
2. To know better the conditions and underlying causes leading to the occurrence of high levels of incidence and prevalence of STIs and HIV/AIDS in Africa.
3. To recognise and understand the urgent needs for a better dermatological health care in our neighbouring continent.

Description:
Dermatovenerology is most important for public health in Africa. Due to a series of geographical, climatic and socio-economic conditions bacterial and fungal skin infections are most common and the recognition of inflammatory dermatosis is difficult in pigmented skin in countries with hot climates. Also, the incidence and prevalence of STIs and HIV/AIDS is high and their control requires long-term efforts. On the other hand, in the majority of African countries the number of practicing Dermatovenerologists is minimal, if any at all, particularly in the Subsaharan part of the continent.  In this area of our world there is a tremendous need for improving the level of skin health care, since a large number of populations in Africa suffer due to lack of updated knowledge, lack of facilities and lack of appropriate drugs. Major aim of this session is to contribute for recognizing the needs of our neighbouring continent, increase the awareness of our European colleagues for the face of Dermatology in Africa, and prepare ourselves to help.

13.00	S44.1	Introduction: Status and Challenges of Skin Disease in Africa. C.E.Orfanos (Berlin, Germany)
13.12	S44.2	Dermatology in Egypt: Incidence of Characteristic Dermatosis. A.Abdel-Halim (Cairo, Egypt)
13.27	S44.3	Sexually Transmitted Infections and their Management in an African Setting. J.Masenga (Moshi, Tanzania)
13.42	S44.4	HIV and HIV-associated  Skin Disease in Ethiopia. S.Beyene (Addis Abbaba, Ethiopia)
13.54	S44.5	The Drama of HIV/AIDS in South Africa. P.N.Naidu (Durban, South Africa)
14.09	S44.6	Closing Remarks: Major Needs of Dermatology in Africa. A.Morrone (Rome , Italy)
14.21		Discussion

S45 - Sexual Health
Saturday, 19 May 2007
13.00 – 14.30  Hall F2

Chairs:  A.J. Robinson (London, UK)
Co-Chairs: C. Bunker (London, UK), G. Stary (Vienna, Austria)

Learning Objectives:
Following this session, the attendee will be able to:

1. understand a range of sexual health issues affecting Europe
2. formulate a differential diagnosis and management plan for men with sexual problems
3. have insight into specific problems of adolescents in relation to sexual health and how to address them
4. recognise syphilis presentations and undertake management in the current epidemic affecting Europe
5. appreciate the need to improve knowledge and skills across a range of providers of care for those at risk of or with sexually transmitted infections using HPV as an example 

Description:
The symposium will provide new information to everyone on a selection of the sexual health issues facing Europe. It will touch on a range of subjects some of which are rarely heard about in EADV congresses but are fundamentally important to providing good health care in dermatovenereology practice.  The role of specialists is to look after individuals but in venereology, a public health perspective is needed to control infections. This symposium is designed to bring other aspects of sexual health to the fore by raising awareness and interactive discussion

13.00	S45.1	Male Dyspareunia. C. Bunker (London, UK)
13.20	S45.2	Sexually Transmitted Infections and Adolescents. O. WiIliams (Cardiff, UK)
13.40	S45.3	Syphilis Re-emergence in Europe. N. Tsankov (Sofia, Bulgaria)
14.00	S45.4	Clinicians' and Consumers Understanding of HPV; a European Perspective. A. Robinson (London, UK)

S46 - EADV President’s Symposium
Friday, 18 May 2007
9.15 – 10.45  Hall K

Chair:  A. Giannetti (Modena, Italy)
Co-Chairs: A. Katsambas (Athens, Greece), J. Ring (Munich, Germany)

Description:
The arguments chosen for this unusual symposium, until last year dedicated to the relationships of the presidents of the European dermatological societies on the conditions of the respective associations, concern the two new aspects of therapeutic technology (electrochemotherapy) and diagnostic technology (in vivo Laser Confocal Microscopy) and a therapeutic application with an “old” drug (sirolimus), which are deeply changing the clinical attitudes of dermatologists.

The results of electrochemotherapy in the treatment of cutaneous and subcutaneous metastases are particularly interesting and positive: such results will be discussed by Prof. Louis Mir from the institute G. Roussy of Paris, who is the top international expert in the field. Prof. Ricardo Garimberti from Buenos Aires collected an extremely large number of case histories at a world level in the treatment of organ transplants with sirolimus and demonstrated a clear reduction in the predominance of cutaneous tumours in transplant patients.

Prof. Giovanni Pellacani from Modena accumulated a wide experience in the use of in vivo laser confocal microscopy in pigmented skin tumours, comparing clinical, dermatoscopic and dermopathologic data for a more and more precise early diagnosis of melanomas.

It is expected that the meeting will arouse a wide interest among the participants for the newness of the arguments and the acknowledged experience of the lecturers.

9.15	S46.1	Sirolimus in transplanted patients and relations with the prevention of skin cancer. R. Galimberti (Buenos Aires, Argentina)
9.45	S46.2	Electrochemoterapy of skin metastasis. L.M. Mir (Villejuif, France)
10.15	S46.3	In vivo confocal microscopy of pigmented skin lesions. G. Pellacani (Modena, Italy)

S48 - Hot topics from the Poster Hall
Saturday, 19 May 2007
13.00 – 14.30  Hall G

Chair:  D.F. Murrell (Sydney, Australia)
Co-Chair: G. Murphy (Dublin, Ireland)

Learning Objectives:
After the session, the attendee will:

1. know about the latest original clinical studies in dermatology
2. hear some unusual case reports of new conditions
3. learn new bench to bedside pathogenesis studies

Description:
The local scientific committee of the EADV ranked the submitted posters into four gradings. The top 100 of those were reviewed by the co-chairs and re-ranked for scientific merit, novelty and interest. The authors of these were invited to present their work orally as well as in poster format. This is a new concept for the EADV. The poster numbers are listed so that attendees may read the posters in detail in advance. The posters will be marked as being
selected for this symposium.

13.00	S48.1	P524 Keratin 9 mutation in palmoplantar keratoderma with knuckle pads. G. Leigheb. (Novara, Italy)
13.09	S48.2	P199 Potential role of antigen-specific T cells in the pathogenesis of vulval lichen sclerosus. M. Baldo (Oxford, UK)
13.18	S48.3	P206 ISA247: Continued safety and efficacy after 60 weeks of continuous therapy in plaque psoriasis by SGA. K. Papp (Waterloo, Canada)
13.27	S48.4	P1490 Gene and protein expression profiles in COP-1 silenced human keratinocytes after UVB irradiation. A. Kinyo (Szeged, Hungary)
13.36	S48.5	P1315 HLA-Cw6 and TNF-a polymorphisms may help predict response to biologic therapy in patients with chronic plaque psoriasis. W.P. Gulliver (St John’s, Canada)
13.45	S48.6	P1242 Interleukin 13 promoter gene polymorphism in mastocytosis. B. Nedoszytko (Gdansk, Poland).
13.54	S48.7	P554 Morphological spectrum of primary cutaneous anaplastic large T cell lymphoma: an histopathological study on 66 biopsy specimens from 47 patients with report on rare variants. C. Massone (Graz, Austria)
14.03	S48.8	P820 Randomised clinical trial of 5-methylaminolevulinate - Photodynamic therapy (MAL-PDT) versus simple excision surgery for superficial Basal Cell Carcinoma (sBCC).R.M. Szeimies (Regensburg, Germany)
14.12	S48.9	P1475 Successful sublingual immunotherapy with birch pollen has limited effects on concomitant food allergy to apple and the immune response to the Bet v 1-homologue Mal d 1. T. Kinaciyan (Vienna, Austria)
14.21	S48.10	P1085 Comparison of healthcare costs in patients with psoriatic arthritis who received etanercept, etanercept plus methotrexate, infliximab, or infliximab plus methotrexate. O. Dabbous (Horsham, USA)